We are live on
!
Find out more
SCM
Silverarc Capital Management Portfolio holdings
AUM
$962M
1-Year Est. Return
524.64%
This Fund
S&P 500
This Quarter
Est. Return
+33.44%
1 Year Est. Return
+524.64%
3 Year Est. Return
+2,765.44%
5 Year Est. Return
+10,523.08%
10 Year Est. Return
–
AUM
$962M
AUM Growth
-$17.7M
(-1.8%)
Cap. Flow
-$105M
Cap. Flow
% of AUM
-10.94%
Top 10 Holdings %
Top 10 Hldgs %
42.32%
Holding
98
New
25
Increased
18
Reduced
27
Closed
25
Avg Time Held Equity + Options
4
quarters
Top 10 Avg Time Held Equity + Options
1
quarter
Top 20 Avg Time Held Equity + Options
2.3
quarters
Avg Time Held Equity only
4.4
quarters
Top 10 Avg Time Held Equity only
1
quarter
Top 20 Avg Time Held Equity only
2.3
quarters
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Enliven Therapeutics
ELVN
|
+$20.8M |
| 2 |
Sagimet Biosciences
SGMT
|
+$19.9M |
| 3 |
Ascendis Pharma A/S
ASND
|
+$19.1M |
| 4 |
Celcuity
CELC
|
+$16.5M |
| 5 |
Oruka Therapeutics
ORKA
|
+$13.5M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
KalVista Pharmaceuticals
KALV
|
+$57.9M |
| 2 |
Nuvalent
NUVL
|
+$36.4M |
| 3 |
Dianthus Therapeutics
DNTH
|
+$23.1M |
| 4 |
CNTA
Centessa Pharmaceuticals
CNTA
|
+$18.5M |
| 5 |
Kodiak Sciences
KOD
|
+$17.3M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 91.68% |
| 2 | Miscellaneous | 6.61% |
| 3 | Financials | 1.7% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
51
Artiva Biotherapeutics
ARTV
$308M
| $5.09M | 0.53% |
+525,000
| New | +$4.78M |
2026 Q2
0 quarters
|
|
52
Contineum Therapeutics
CTNM
$317M
| $4.85M | 0.5% |
296,135
-5,594
| -2% | -$73.3K |
2025 Q3
3 quarters
|
|
53
uniQure
QURE
$1.48B
| $4.84M | 0.5% |
+105,000
| New | +$2.75M |
2026 Q2
0 quarters
|
|
54
Research Alliance Corp III
RACC
$92.4M
| $3.85M | 0.4% |
+360,000
| New | +$3.75M |
2026 Q2
0 quarters
|
|
55
Abeona Therapeutics
ABEO
$258M
| $3.77M | 0.39% |
610,407
-38,535
| -6% | -$212K |
2025 Q2
4 quarters
|
|
56
Insmed
INSM
$21.1B
| $3.67M | 0.38% |
34,438
-1,412
| -4% | -$171K |
2020 Q4
22 quarters
|
|
57
Karyopharm Therapeutics
KPTI
$9.69M
| $2.91M | 0.3% |
+297,460
| New | +$2.58M |
2026 Q2
0 quarters
|
|
58
PUT
Kymera Therapeutics
KYMR
$8.87B
| $2.87M | 0.3% |
+25,000
| New | +$2.15M |
2026 Q2
0 quarters
|
|
59
CAMP4 Therapeutics
CAMP
$215M
| $2.86M | 0.3% |
653,594
| – | – |
2026 Q1
1 quarter
|
|
60
Elutia
ELUT
$34.2M
| $2.15M | 0.22% |
2,192,980
-305,040
| -12% | -$324K |
2024 Q1
9 quarters
|
|
61
Revolution Medicines
RVMD
$40.4B
| $1.87M | 0.19% |
+10,000
| New | +$1.46M |
2026 Q2
0 quarters
|
|
62
Sionna Therapeutics
SION
$198M
| $1.87M | 0.19% |
42,478
+3,061
| +8% | +$122K |
2025 Q1
5 quarters
|
|
63
PUT
Absci
ABSI
$1.56B
| $1.83M | 0.19% |
+157,600
| New | +$888K |
2026 Q2
0 quarters
|
|
64
TELA Bio
TELA
$48.1M
| $1.6M | 0.17% |
2,137,201
-122,111
| -5% | -$99.9K |
2023 Q1
13 quarters
|
|
65
Achieve Life Sciences
ACHV
$722M
| $1.48M | 0.15% |
+227,178
| New | +$1.08M |
2026 Q2
0 quarters
|
|
66
CALL
Fulcrum Therapeutics
FULC
$281M
| $1.43M | 0.15% |
391,900
| – | – |
2025 Q4
2 quarters
|
|
67
Fractyl Health
GUTS
$53.4M
| $1.3M | 0.14% |
136,498
-5,304
| -4% | -$45.3K |
2024 Q1
9 quarters
|
|
68
Connect Biopharma Holdings
CNTB
$57.9M
| $1.3M | 0.13% |
+545,000
| New | +$1.32M |
2026 Q2
0 quarters
|
|
69
Crescent Biopharma
CBIO
$480M
| $1.06M | 0.11% |
59,104
-71,396
| -55% | -$1.39M |
2026 Q1
1 quarter
|
|
70
Cellectar Biosciences
CLRB
$13.1M
| $894K | 0.09% |
+321,728
| New | +$900K |
2026 Q2
0 quarters
|
|
71
Foghorn Therapeutics
FHTX
$110M
| $224K | 0.02% |
+45,975
| New | +$204K |
2026 Q2
0 quarters
|
|
72
Adagio Medical Holdings
ADGM
$3.44M
| $146K | 0.02% |
224,360
-27,612
| -11% | -$27K |
2025 Q4
2 quarters
|
|
73
DELISTED
Rocket Pharmaceuticals Warrant
RCKTW
| $356 | ﹤0.01% |
104,828
| – | – |
2023 Q1
13 quarters
|
|
74
Annexon
ANNX
$726M
| – | – |
-496,461
| Closed | -$2.75M | – |
|
|
75
CALL
Celcuity
CELC
$3.09B
| – | – |
-54,500
| Closed | -$6.22M | – |
|
Similar funds
LGP
PL
LAM
ACP
GIG
AAP
BEAM
RAM
Silverarc Capital Management's Q2 2026 Portfolio in Review
As of Q2 2026, Silverarc Capital Management held 98 positions worth $962M, down 1.8% from $980M the previous quarter. Its ten largest holdings account for 42% of the portfolio.
Silverarc Capital Management withdrew a net $105M in Q2 2026, closing 25 positions and reducing 27 holdings. Its most notable exit was KalVista Pharmaceuticals, an estimated $57.9M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 92% of assets, up from 85% a quarter earlier, followed by Miscellaneous and Financials.
Against the trend, Silverarc Capital Management opened a new position in Enliven Therapeutics worth $24.8M.
- Silverarc Capital Management's largest Q2 2026 buy was Enliven Therapeutics: 489,382 shares worth $24.8M.
- Silverarc Capital Management added most to Ascendis Pharma A/S in Q2 2026, an estimated $19.1M increase.
- Silverarc Capital Management's biggest Q2 2026 reduction was Dianthus Therapeutics, cutting an estimated $23.1M.
- Silverarc Capital Management fully exited KalVista Pharmaceuticals in Q2 2026, selling an estimated $57.9M.
- Silverarc Capital Management's ten largest holdings make up 42% of its $962M portfolio in Q2 2026.
- Silverarc Capital Management opened 25 new positions and closed 25 in Q2 2026.
- Silverarc Capital Management's portfolio value fell 1.8% quarter-over-quarter to $962M.
Based on Silverarc Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.